SciSparc and Clearmind publish patent application for binge disorders

SciSparc Ltd. (NASDAQ: SPRC) announced that its collaboration with Clearmind Medicine Inc. (NASDAQ: CMND) resulted in the publication of a U.S. patent application by the United States Patent and Trademark Office. The patent application covers a combination therapy using MEAI (5-methoxy-2-aminoindane) and N-Acylethanolamines, including Palmitoylethanolamide (PEA), for treating binge behavior disorders.

The patent application addresses multiple binge behaviors including excessive alcohol consumption, eating disorders, tobacco use, compulsive shopping, and problematic sexual conduct. The combination therapy utilizes MEAI's psychedelic properties to reduce impulsivity and reward-seeking behavior, while incorporating PEA's anti-inflammatory and neuroprotective effects.

The collaboration between the two companies focuses on PEA-MEAI combinations for conditions including alcohol use disorder, cocaine addiction, obesity, and depression. According to the company's statement, preclinical data supports the therapy's potential efficacy in reducing binge episodes while maintaining natural reward pathways.

SciSparc is a clinical-stage pharmaceutical company developing cannabinoid-based therapies for central nervous system disorders and rare diseases. The company's current drug development programs include SCI-110 for Tourette Syndrome and Alzheimer's disease, and SCI-210 for autism and status epilepticus.

Clearmind Medicine is a clinical-stage psychedelic pharmaceutical company focused on developing novel psychedelic-derived therapeutics. The company's intellectual portfolio includes 19 patent families with 31 granted patents.

You May Also Be Interested In

• Qualcomm to launch data center CPU in mid-2028 - Data Center Chief
• Brera Holdings directors disclose share positions amid takeover offer
• Qualcomm Says Dragonfly C1000 Cpus Coming In 2028